• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Mukadam Sophie claimed ownership of 6,016 shares (SEC Form 3)

    1/3/25 5:39:57 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BNTC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Mukadam Sophie

    (Last) (First) (Middle)
    C/O BENITEC BIOPHARMA INC.
    3940 TRUST WAY

    (Street)
    HAYWARD CA 94545

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    01/01/2025
    3. Issuer Name and Ticker or Trading Symbol
    Benitec Biopharma Inc. [ BNTC ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Operating Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock, par value $0.0001 per share 6,016 I By spouse
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Options (right to buy) (1) 12/08/2030 Common Stock 141 $50.66 D
    Options (right to buy) (2) 06/13/2031 Common Stock 1,034 $79.9 D
    Options (right to buy) (3) 06/12/2033 Common Stock 5,294 $3.91 D
    Options (right to buy) (4) 03/05/2034 Common Stock 100,000 $5.21 D
    Options (right to buy) (5) 12/27/2034 Common Stock 300,000 $12 D
    Explanation of Responses:
    1. The stock options vested in three substantially equal installments on December 9, 2021, December 9, 2022 and December 9, 2023.
    2. The stock options vested in three substantially equal installments on June 14, 2022, June 14, 2023, and June 14, 2024.
    3. Stock options for 1,764 shares vested on June 13, 2024. The remainder of the stock options will vest in two substantially equal installments on June 13, 2025 and June 13, 2026.
    4. The stock options will vest in three substantially equal installments on March 6, 2025, March 6, 2026, and March 6, 2027.
    5. The stock options will vest in sixteen substantially equal quarterly installments commencing on March 31, 2025.
    Remarks:
    Exhibit 24 - Power of Attorney
    /s/ Louis Rambo, Attorney-in-Fact for Sophie Mukadam 01/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BNTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNTC

    DatePrice TargetRatingAnalyst
    12/16/2024$28.00Buy
    H.C. Wainwright
    12/13/2024$30.00Outperform
    Robert W. Baird
    10/16/2024$35.00Outperform
    Oppenheimer
    9/12/2024$17.00Buy
    Guggenheim
    7/22/2024$13.00Outperform
    Leerink Partners
    6/13/2024$30.00Overweight
    Piper Sandler
    2/17/2022$10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BNTC
    Leadership Updates

    Live Leadership Updates

    See more
    • Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

      HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

      7/1/24 7:00:00 AM ET
      $BHVN
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Suvretta Capital Management, Llc bought $211,736 worth of shares (16,497 units at $12.83) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      4/2/25 4:37:02 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Suvretta Capital Management, Llc bought $11,700,000 worth of shares (900,000 units at $13.00) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      3/28/25 4:51:41 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Suvretta Capital Management, Llc bought $527,174 worth of shares (47,520 units at $11.09) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      12/26/24 4:28:03 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    SEC Filings

    See more
    • SEC Form S-3 filed by Benitec Biopharma Inc.

      S-3 - Benitec Biopharma Inc. (0001808898) (Filer)

      5/23/25 4:32:52 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Benitec Biopharma Inc.

      SCHEDULE 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

      5/15/25 4:38:23 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Benitec Biopharma Inc.

      SCHEDULE 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

      5/14/25 12:49:27 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Suvretta Capital Management, Llc bought $211,736 worth of shares (16,497 units at $12.83) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      4/2/25 4:37:02 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Suvretta Capital Management, Llc bought $11,700,000 worth of shares (900,000 units at $13.00) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      3/28/25 4:51:41 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Buchi J Kevin gifted 103,626 shares and received a gift of 103,626 shares, decreasing direct ownership by 100% to 284 units (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      3/13/25 4:43:09 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Financials

    Live finance-specific insights

    See more
    • Benitec Biopharma Releases Third Quarter 2025 Financial Results

      HAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its third fiscal quarter ended March 31, 2025. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission. "We are profoundly honored to be closely engaged with the OPMD patient community and are thankful for the support of the Subjects and their families as we remain focused on the continued development

      5/14/25 7:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

      -Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025- HAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its second fiscal quarter ended December 31, 2024. The Company has filed its

      2/14/25 8:10:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

      -Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29th Annual Congress of the World Muscle Society- -Third Subject Safely Treated with the Low-Dose of BB-301 in October 2024, and Fourth Subject Expected to Receive Treatment with the Low-Dose of BB-301 in December 2024 HAYWARD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing no

      11/14/24 4:30:00 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Benitec Biopharma with a new price target

      H.C. Wainwright initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $28.00

      12/16/24 6:46:22 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Benitec Biopharma with a new price target

      Robert W. Baird initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $30.00

      12/13/24 7:25:56 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Benitec Biopharma with a new price target

      Oppenheimer initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $35.00

      10/16/24 7:20:22 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

      SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

      12/6/24 1:47:28 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Benitec Biopharma Inc.

      SC 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)

      11/18/24 4:36:00 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

      SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

      11/14/24 1:37:20 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Benitec Biopharma Releases Third Quarter 2025 Financial Results

      HAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its third fiscal quarter ended March 31, 2025. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission. "We are profoundly honored to be closely engaged with the OPMD patient community and are thankful for the support of the Subjects and their families as we remain focused on the continued development

      5/14/25 7:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

      HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") "Silence and Replace" platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct offering of 900,000 shares of its common stock with long-term investor Suvretta Capital. Each share of common stock is being sold at an offering price of $13.00 and each pre-funded warra

      3/25/25 8:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

      -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 2, with Subject 2 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Symptom Burden- -Clinically Significant Improvements in Swallowing Function Achieved 3-months Post-Treatment with BB-301 for Subject 3, with Subject 3 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Symptom Burden- -Positive Interim Clinical Study Results

      3/19/25 7:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care